Transcatheter aortic valve-in-valve implantation for degenerated Mitroflow bioprostheses can result in coronary occlusion, as demonstrated in two reported cases.
Case Report (n=2)
This report provides the first evidence of coronary occlusion following TAVI valve-in-valve therapy, specifically with degenerated Mitroflow bioprostheses, highlighting the importance of pre-procedural anatomical assessment.
Transcatheter aortic valve implantation (TAVI) for failed surgical bioprostheses, or "valve-in-valve" implantation, is a therapeutic option for high-risk patients. While coronary occlusion during TAVI for native aortic stenosis has been described, in the setting of valve-in-valve implantation the bioprosthetic posts may be protective against this complication. We describe the first two cases of coronary occlusion following valve-in-valve therapy, both occurring during treatment of degenerated Mitroflow bioprostheses. Aortic root anatomy, coronary ostial position, and the specifics of the bioprosthetic valve type need to be considered in assessing and preventing this rare complication.
Gurvitch et al. (Tue,) conducted a case report in Failed surgical bioprostheses (n=2). Transcatheter aortic valve-in-valve implantation was evaluated on Coronary occlusion. Transcatheter aortic valve-in-valve implantation for degenerated Mitroflow bioprostheses can result in coronary occlusion, as demonstrated in two reported cases.